Full Year 2023 Investor Presentation

79 Investor presentation Full year 2023 Oral amycretin phase 1 trial was successfully completed in Q1 2024 Amycretin is a GLP-1 and amylin receptor co-agonist intended for oral delivery Phase 1 single dose and multiple dose trial for oral amycretin in obesity initiated in 2022 GLP-1 receptor People Novo NordiskⓇ living with Multiple ascending dose cohorts overweight or obesity, and otherwise Single ascending dose cohorts healthy Trial objectives Amylin receptor • Assess the safety and tolerability of oral amycretin Assess PK profile and explore PD effects Utilising the SNAC technology PK: Pharmacokinetics; PD: Pharmacodynamics Next steps Further clinical development currently being evaluated

View entire presentation